...
首页> 外文期刊>BMC Endocrine Disorders >Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C
【24h】

Takotsubo cardiomyopathy and transient thyrotoxicosis during combination therapy with interferon-alpha and ribavirin for chronic hepatitis C

机译:Takotsubo心肌病和干扰素-α和利巴韦林联合治疗慢性丙型肝炎期间的短暂甲状腺毒症

获取原文

摘要

Background Thyroid dysfunction is a common complication of chronic hepatitis C (CHC) and its therapy . Takotsubo cardiomyopathy (TCM) is a multifactorial, stress related cardiomyopathy, rarely reported in association with thyrotoxicosis. Simultaneous occurrence of TCM and thyrotoxicosis due to hepatitis C and its treatment has never been reported. Case presentation A 47-year-old woman was admitted for acute chest pain, dyspnea, palpitations and diaphoresis. She had been diagnosed with CHC and had undergone 7 months of IFNα and Ribavirin therapy. At admission electrocardiogram (ECG) showed ST segment elevation, negative T waves and troponin was elevated suggesting ST segment elevation myocardial infarction (STEMI). Echocardiography demonstrated left ventricular apical akinesia and ballooning, with a left ventricular ejection fraction (LVEF) of 35%. Contrast angiography showed normal epicardial coronaries, yet a ventriculogram revealed left ventricular apical ballooning, consistent with TCM. Cardiac MRI showed left ventricle apical ballooning and no late enhancement suggesting the absence of any edema, scar or fibrosis in the left myocardium. She was diagnosed with non-autoimmune destructive thyroiditis: TSH=0.001 mU/L, free T4=2.41 ng/dl, total T3=199 ng/dl and negative thyroid antibodies. The thyroid ultrasonography showed a diffuse small goiter, no nodules and normal vascularization of the parenchyma. Following supportive treatment she experienced a complete recovery after a few weeks and she successfully completed her antiviral treatment, with no thyroid or cardiovascular dysfunction ever since. In patients treated with IFNα for CHC, the prevalence of thyroid dysfunction varies between 2.5–45.3% of cases. TCM is a stress related cardiomyopathy characterized by elevated cardiac enzymes, normal coronary angiography and an acute, transient, left ventricular apical dysfunction that mimics myocardial infarction. Most of the patients survive the initial acute event, typically recover normal ventricular function within one to four weeks and have a favorable outcome, as was the case with our patient. Thyrotoxicosis induced stress cardiomyopathy is rare and has been mostly reported in association with Graves’ disease, thyroid storm, thyrotoxicosis factitia or following radioiodine therapy for toxic multinodular goiter. Conclusion Routine thyroid screening should be done in patients receiving IFN-alpha and Ribavirin for CHC and thyrotoxicosis should be considered as a possible and treatable underlying cause of TCM.
机译:背景甲状腺功能不全是慢性丙型肝炎(CHC)及其治疗的常见并发症。 Takotsubo心肌病(TCM)是一种与压力相关的多因素心肌病,很少见与甲状腺毒症有关。从未报道过由丙型肝炎引起的中医药和甲状腺毒症同时发生及其治疗。病例介绍一名47岁的妇女因急性胸痛,呼吸困难,心和发汗而入院。她被诊断出患有慢性丙型肝炎,并接受了7个月的IFNα和利巴韦林治疗。入院时心电图(ECG)显示ST段抬高,负T波和肌钙蛋白升高,提示ST段抬高心肌梗死(STEMI)。超声心动图显示左心室运动障碍和球囊扩张,左心室射血分数(LVEF)为35%。造影造影显示心外膜冠状动脉正常,而心室造影显示左心尖顶气囊,与中医相符。心脏MRI显示左心室心尖球囊扩张,未见晚期增强,提示左心肌无任何水肿,疤痕或纤维化。她被诊断出患有非自身免疫性破坏性甲状腺炎:TSH = 0.001 mU / L,游离T4 = 2.41 ng / dl,总T3 = 199 ng / dl,甲状腺抗体阴性。甲状腺超声检查显示弥漫性小甲状腺肿,无结节,实质实质血管正常。接受支持治疗后,她在几周后完全康复,并且成功完成了抗病毒治疗,此后没有甲状腺或心血管功能障碍。在接受IFNα治疗CHC的患者中,甲状腺功能障碍的患病率在2.5%至45.3%之间。中医是一种与压力有关的心肌病,其特征在于心脏酶升高,冠状动脉造影正常和模拟心肌梗塞的急性,短暂性左心室心尖功能障碍。多数患者在最初的急性事件中幸存下来,通常在1至4周内恢复正常的心室功能,并取得了良好的效果,就像我们的患者一样。甲状腺毒症引起的应激性心肌病很少见,据报道主要与格雷夫斯病,甲状腺风暴,甲状腺毒症事实或放射性碘治疗中毒性多结节性甲状腺肿有关。结论接受IFN-α和利巴韦林的CHC患者应常规进行甲状腺筛查,甲状腺毒症应被认为是中医可能且可治疗的潜在原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号